NCT06136988View on ClinicalTrials.gov

A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

December 31, 2023

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2028

Conditions
Locally Advanced Unresectable Esophageal Squamous Carcinoma
Interventions
DRUG

Docetaxel for Injection (Albumin-bound)

Docetaxel for Injection (Albumin-bound) 60 or 75 mg/m\^2, Intravenous infusion, Q3W

DRUG

SG001

Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, 360 mg, Intravenous infusion, Q3W

DRUG

Cisplatin for injection

Cisplatin for injection, 25 mg/m\^2, Intravenous infusion, D1-D3, Q3W

DRUG

Paclitaxel

Paclitaxel 135 mg/m\^2, Intravenous infusion, Q3W

RADIATION

Simultaneous Radiotherapy

Radiotherapy (28×1.8Gy)

Trial Locations (2)

Unknown

Shandong Tumor Hospital, Jinan

Tianjin cancer institute &hospital, Tianjin

All Listed Sponsors
lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY

NCT06136988 - A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma. | Biotech Hunter | Biotech Hunter